Table 3 Indirect costs of TNBC in two studies
From: A systematic literature review on direct and indirect costs of triple-negative breast cancer
Studies | Authors | Country of study | Type of indirect cost | Type of study | Study perspective | Approach | Cost |
|---|---|---|---|---|---|---|---|
The economic burden of metastatic breast cancer in Spain | De las Heras et al. (2020) [37] | Spain | Lost productivity | Observational cohort study | Payer | An incidence-based cost-of-illness model | Monthly per patient ($9.096) per patient over 5 years ($186,535) |
The Economic Burden of Recurrence in Triple- Negative Breast Cancer Among Working Age Patients in the United States | Sieluk et al. (2022) [38] | USA | Work loss | Retrospective observational cohort study | Payer; patient | OptumHealth Reporting and Insights claims database | Absenteeism costs were $261 per patient for patients without recurrence, $498.375 for patients with locoregional recurrence, and $1060.875 for patients with meta- static recurrence |